Insider · CIK 0001885914
Ran Zheng
Files at CRBU (Caribou Biosciences, Inc.). First filing -, latest -.
In brief
Ran Zheng files SEC Form 4 as director at CRBU (Caribou Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ran Zheng has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | CRBU Caribou Biosciences, Inc. | AGrant or award Option to purchase Common Stockderivative | +45,000 | $0.00 | $0 | 45,000 | Feb 20, 2026 |
| Feb 20, 2025 | CRBU Caribou Biosciences, Inc. | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
Questions about Ran Zheng
Answered from the filings on this page, as of the latest one.
Is Ran Zheng buying or selling?
Ran Zheng has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ran Zheng's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ran Zheng has 0.
Where does Ran Zheng file Form 4?
Ran Zheng has filed Form 4 at CRBU (Caribou Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.